These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36148258)

  • 1. Managing Heart Failure With Reduced Ejection Fraction in Patients With Chronic Kidney Disease: A Case-Based Approach and Contemporary Review.
    Barry AR
    CJC Open; 2022 Sep; 4(9):802-809. PubMed ID: 36148258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.
    Beldhuis IE; Lam CSP; Testani JM; Voors AA; Van Spall HGC; Ter Maaten JM; Damman K
    Circulation; 2022 Mar; 145(9):693-712. PubMed ID: 35226558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
    Jhund PS; Solomon SD; Docherty KF; Heerspink HJL; Anand IS; Böhm M; Chopra V; de Boer RA; Desai AS; Ge J; Kitakaze M; Merkley B; O'Meara E; Shou M; Tereshchenko S; Verma S; Vinh PN; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Bengtsson O; Langkilde AM; Sjöstrand M; McMurray JJV
    Circulation; 2021 Jan; 143(4):298-309. PubMed ID: 33040613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
    Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV
    JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal protection in chronic heart failure: focus on sacubitril/valsartan.
    Pontremoli R; Borghi C; Perrone Filardi P
    Eur Heart J Cardiovasc Pharmacother; 2021 Sep; 7(5):445-452. PubMed ID: 33822031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacologic treatment of heart failure with reduced ejection fraction in chronic kidney disease].
    Heine GH; Rogacev KS
    Dtsch Med Wochenschr; 2019 Dec; 144(24):1714-1720. PubMed ID: 31791077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
    Zannad F; Ferreira JP; Pocock SJ; Zeller C; Anker SD; Butler J; Filippatos G; Hauske SJ; Brueckmann M; Pfarr E; Schnee J; Wanner C; Packer M
    Circulation; 2021 Jan; 143(4):310-321. PubMed ID: 33095032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker.
    Tan NY; Deng Y; Yao X; Sangaralingham LR; Shah ND; Rule AD; Burnett JC; Dunlay SM; Sangaralingham SJ
    Mayo Clin Proc Innov Qual Outcomes; 2021 Apr; 5(2):286-297. PubMed ID: 33997628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction.
    McCallum W; Tighiouart H; Ku E; Salem D; Sarnak MJ
    Am J Kidney Dis; 2020 Jan; 75(1):21-29. PubMed ID: 31303349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF.
    Peikert A; Vaduganathan M; Mc Causland F; Claggett BL; Chatur S; Packer M; Pfeffer MA; Zannad F; Lefkowitz MP; Pieske B; Düngen HD; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2022 May; 24(5):794-803. PubMed ID: 35119183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study.
    Jia R; Zhang X; Xu Y; Zheng Z; Jiang L; Zhang X; Sun C; Wu X; Li S; Raj A; Sun D
    Eur J Pharmacol; 2022 Aug; 928():175053. PubMed ID: 35709921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
    Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L
    Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study.
    Hsiao FC; Lin CP; Yu CC; Tung YC; Chu PH
    Front Cardiovasc Med; 2022; 9():794707. PubMed ID: 35360037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.
    Shen L; Kristensen SL; Bengtsson O; Böhm M; de Boer RA; Docherty KF; Inzucchi SE; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez MFA; O'Meara E; Nicolau JC; Petrie MC; Ponikowski P; Sabatine MS; Schou M; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV
    JACC Heart Fail; 2021 Apr; 9(4):254-264. PubMed ID: 33549554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
    Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
    J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.
    Solomon SD; Jhund PS; Claggett BL; Dewan P; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Inzucchi SE; Desai AS; Bengtsson O; Lindholm D; Sjostrand M; Langkilde AM; McMurray JJV
    JACC Heart Fail; 2020 Oct; 8(10):811-818. PubMed ID: 32653447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.